Clinical Trial

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of Baricitinib in the treatment of frontal fibrosing alopecia (FFA).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2026-10-31 2026-07-08
minor Completion pushed: 2027-07-31 -> 2027-09-30 2026-07-08
Trial Details
NCT Number NCT06240351
Lead Sponsor University of Alabama at Birmingham
Collaborators: Eli Lilly and Company
Conditions Frontal Fibrosing Alopecia
Enrollment 15 participants
Start Date 2024-04-22
Primary Completion 2026-10-31 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07